Clinical Trial Update: Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome (WAS) [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial evaluating a reduced-toxicity myeloablative conditioning regimen for Wiskott-Aldrich Syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wiskott-aldrich Syndrome

Snippet

Sponsor: The Korean Society of Pediatric Hematology Oncology | Conditions: Wiskott-Aldrich Syndrome | Phase 1, Phase 2 | Status: COMPLETED